Acta Neuropharmacologica ›› 2016, Vol. 6 ›› Issue (4): 24-30.DOI: 10.3969/j.issn.2095-1396.2016.04.004

Previous Articles     Next Articles

Research Progress on Pharmacological Action and Dosage Form of Tanshinone II A on Cardiovascular System

HOU Wen-shu,ZHANG Li   

  1. The Department of Pharmacy,Hebei North University, Zhangjiakou,075000,China
  • Online:2016-08-26 Published:2016-08-31
  • Contact: 张力,男,教授,硕士生导师;研究方向:神经药理学;Tel:+86-0313-4029188,E-mail:hbnulzhang@126.com
  • About author:侯文书,女,硕士研究生;研究方向:神经药理学;E-mail:houws0506@163.com
  • Supported by:

    国家自然基金项目(No.81202192),河北省中医药管理局项目(No.2013075),河北省卫生厅项目(No.20130034)

Abstract: Tanshinone Ⅱ A is not only a kind of important fat-soluble extract which comes from Labiatae Salvia miltiorrhiza but also a kind of the most effective pharmacological active ingredients. So many experiments and clinical studies have shown that tanshinone Ⅱ A can prevent or attenuate the progress of multiple diseases including cardiovascular disease,cancer,neonatal hypoxic ischemic encephalopathy,liver fibrosis and neurodegenerative disease. With aging of population’s development,cardiovascular disease has become a common disease which threatens human health ranking fi rst of all causes of death. Tanshinone Ⅱ A has the effects of anti-atherosclerosis,anti-myocardial ischemia,anti-arrhythmic,repair of vascular endothelial cells and improvement of coronary blood circulation in cardiovascular system,however,tanshinone Ⅱ A is a fat-soluble component with the disadvantages of poor oral absorption and low bioavailability. Therefore,in order to improve the present situation of tanshinone Ⅱ A ,new dosage forms of tanshinone Ⅱ A should be prepared,such as injectable microemulsions,micro pill,solid dispersions,liposomes,nanoparticles,etc. Therefore,this article summarizes the domestic and international research situation. The results showed the development of new dosage forms made tanshinone Ⅱ A play a greater medical value in the treatment of cardiovascular diseases,providing theoretical guidance for further research.

Key words: tanshinone Ⅱ A , cardiovascular disease, dosage form